ELVN

Enliven Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality0/10
  • Growth↓ 2/10
  • Momentum↑ 7/10
Enliven Therapeutics sales and earnings growth
ELVN Growth
Fair
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↓ 2.65%
  • FCF Y/Y↓ -4.81%
Enliven Therapeutics gross and profit margin trends
ELVN Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC↓ -34.80%
Enliven Therapeutics net debt vs free cash flow
ELVN Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Enliven Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗